中国医药指南
中國醫藥指南
중국의약지남
CHINA MEDICINE GUIDE
2014年
29期
41-41,42
,共2页
艾拉莫德%类风湿关节炎%临床疗效%免疫球蛋白
艾拉莫德%類風濕關節炎%臨床療效%免疫毬蛋白
애랍막덕%류풍습관절염%림상료효%면역구단백
Iguratimod%Arthritis rheumatoid%Clinical effect%Immunoglobulin
目的:对风湿关节炎患者运用艾拉莫德进行治疗,分析其临床疗效,并探讨其对免疫学指标的影响。方法90例活动期类风湿关节炎患者,分别给予50 mg/d的艾拉莫德片(甲组),25 mg/d的艾拉莫德片(乙组)及10毫克/周的甲氨蝶呤(丙组)。在6周及12周时,对三组临床疗效及免疫学指标进行观察与评估。结果甲乙丙三组在用药6周后ACR20开始上升,用药12周之后,在ACR20标准上,甲组为53.3%(16/30),乙组为36.7%(11/30),丙组为50%(15/30),甲组要优于乙组(P<0.05),甲组与丙组对比差异不显著,不具有统计学意义(P>0.05);三组的IgA、IgM以及IgG等免疫学指标均明显改善,而甲乙两组的IgA的改变要显著优于丙组(P<0.05)。结论作为一种慢作用药,艾拉莫德在治疗类风湿关节炎上的效果显著,此药物能够免疫调节B淋巴细胞,抑制免疫球蛋白产生。
目的:對風濕關節炎患者運用艾拉莫德進行治療,分析其臨床療效,併探討其對免疫學指標的影響。方法90例活動期類風濕關節炎患者,分彆給予50 mg/d的艾拉莫德片(甲組),25 mg/d的艾拉莫德片(乙組)及10毫剋/週的甲氨蝶呤(丙組)。在6週及12週時,對三組臨床療效及免疫學指標進行觀察與評估。結果甲乙丙三組在用藥6週後ACR20開始上升,用藥12週之後,在ACR20標準上,甲組為53.3%(16/30),乙組為36.7%(11/30),丙組為50%(15/30),甲組要優于乙組(P<0.05),甲組與丙組對比差異不顯著,不具有統計學意義(P>0.05);三組的IgA、IgM以及IgG等免疫學指標均明顯改善,而甲乙兩組的IgA的改變要顯著優于丙組(P<0.05)。結論作為一種慢作用藥,艾拉莫德在治療類風濕關節炎上的效果顯著,此藥物能夠免疫調節B淋巴細胞,抑製免疫毬蛋白產生。
목적:대풍습관절염환자운용애랍막덕진행치료,분석기림상료효,병탐토기대면역학지표적영향。방법90례활동기류풍습관절염환자,분별급여50 mg/d적애랍막덕편(갑조),25 mg/d적애랍막덕편(을조)급10호극/주적갑안접령(병조)。재6주급12주시,대삼조림상료효급면역학지표진행관찰여평고。결과갑을병삼조재용약6주후ACR20개시상승,용약12주지후,재ACR20표준상,갑조위53.3%(16/30),을조위36.7%(11/30),병조위50%(15/30),갑조요우우을조(P<0.05),갑조여병조대비차이불현저,불구유통계학의의(P>0.05);삼조적IgA、IgM이급IgG등면역학지표균명현개선,이갑을량조적IgA적개변요현저우우병조(P<0.05)。결론작위일충만작용약,애랍막덕재치료류풍습관절염상적효과현저,차약물능구면역조절B림파세포,억제면역구단백산생。
Objective To study the efifcacy of iguratimod in treating rheumatoid arthritis(RA) and analysis the change of immunological indexes. Methods Ninety patients with active RA were allocated to 3 groups:iguratimod 50 mg each day, 25 mg each day or 10 mg MTX each week. Clinical and laboratory parameters were analyzed on 6, 12 weeks. Results After 6 weeks, ACR20 started to rise. After 12 weeks, the ACR20 of the three groups were respectively:50 mg/d dosage group was 53.3%(16/30), 25 mg/d dosage group was 36.7%(11/30), the control group was 50%(15/30), ACR20 was signiifcantly higher in 50 mg/d dosage group than in 25 mg/d dosage group(P<0.05), there was no signiifcant difference between the 50 mg/d dosage group and the control group(P>0.05);IgA, IgM and IgG of three groups all improved, and IgA of 50 mg/d dosage group and 25 mg/d dosage group were more significantly improved compared with the control group (P<0.05). Conclusion Iguratimod is effective in the treatment of rheumatoid arthritis and it can inhibit the produce of immunoglobulin.